Navigation Links
MiStent SES Shown to be Unique in Clinical Setting
Date:10/28/2013

DURHAM, N.C., Oct. 28, 2013 /PRNewswire/ -- Micell Technologies, Inc. today announced that imaging and clinical results from the DESSOLVE I and DESSOLVE II trials of its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES®) were presented at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference held in San Francisco, October 27 – November 1, 2013. The MiStent SES is a thin-strut drug-eluting stent distinguished by a rapidly absorbable coating designed to control drug release, and which was developed to optimize vessel healing in patients with coronary artery disease.

The data presentation, "MiStent: 2-year Randomized Trial Results from a Sirolimus-eluting Stent with a Bioabsorbable Coating," was part of the Scientific Symposium, "Next Generation DES and Bioabsorbable Scaffolds" conducted on Sunday, October 27.  John Ormiston, M.B.Ch.B., Interventional Cardiologist with the Mercy Angiography Unit, Auckland, New Zealand presented the data. Dr. Ormiston is a principal investigator in the DESSOLVE studies.

Two-year follow-up data from the DESSOLVE I and II trials were presented. The DESSOLVE I trial demonstrated minimal progression of late lumen loss between eight and 18 months follow up, with no target lesion MACE events through two years. The DESSOLVE II randomized trial two-year MACE rate was 6.7% for MiStent and 13.3% for Endeavor DES control group. There were no probable or definite stent thromboses related to MiStent use in either trial through two years. Detailed IVUS, angiographic and OCT imaging with endothelial function testing conducted across the two trials demonstrated bare-metal stent type healing with maintenance of normal endothelial function.

Dr. Ormiston commented, "MiStent is the only product in its class to optimize local drug delivery properties by providing up to nine
'/>"/>

SOURCE Micell Technologies
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micell Technologies Receives CE Mark Approval for MiStent SES
2. Micell Technologies Announces Development and Distribution Agreement to Bring MiStent SES to China
3. Early Coronary Artery Healing Advantage of OrbusNeichs Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses
4. Pycnogenol® (French Maritime Pine Bark Extract) Shown To Improve Endothelial Function And Reduce Oxidative Stress In New Clinical Trial
5. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
6. Daily Cocoa Flavanol Consumption Shown to Improve Cognitive Function in Older Adults
7. Israeli Innovation Shown to Demonstrate Reduction in Headaches and Neck Pain
8. Natural Tree Extract (Larch Arabinogalactan) Shown to Have Statistically Significant Effect in Protecting Immune Health
9. EarlySense System Implementation Shown to Reduce Falls, Decrease Transfers to Hospitals and Increase the Quality of Care for Elderly in Multi-Center Nursing Home Study
10. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
11. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/bf3b6l/electrocardiogram ) has ... - Global Trends, Estimates and Forecasts, 2012-2018" report ... Global Electrocardiogram Devices (ECG) sector is ... North America accounts for nearly 36% ... Europe claims approximately 27% (2018). ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the addition of the ... 2012-2018"  report to their offering. Global Guidewires sector ... North America accounts for nearly ... Europe claims approximately 25% (2018). ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  Immune Pharmaceuticals Inc. ... that its Board of Directors has elected Mr. Daniel Kazado ... who continues as Chief Executive Officer of Immune. Mr. Kazado ... 2013. Immune,s new Chairman, Mr. Daniel Kazado ... shareholders and to continue to support the strategic vision of ...
Breaking Medicine Technology:Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... April 21 Strativa,Pharmaceuticals, the proprietary products ... PRX ) today announced that its development ... a Phase III,study of Loramyc(R) (miconazole Lauriad(R)) ... candidiasis (OPC)., Top line data show ...
... Nostrum, a privately-held,company based in Edison, ... completed its early, primate, proof-of-concept study for ... SMRX11. Nostrum,s,Symmetrix subsidiary, based in Singapore, is ... from the Institute of Microbial,Technology, Chandigarh, India, ...
Cached Medicine Technology:Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis 2Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis 3Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Wittenberg, MD, uses an,investor,s technology to yield the ... 6 When Scottsdale businessman,Warren Kaplan decided a ... had no,idea that an innovative medical product Possis ... gifted interventional radiologist - save his daughter,s life., ...
... Nov. 6 Repligen Corporation,(Nasdaq: RGEN ) ... Phase 2b,clinical trial to evaluate the use of ... bipolar depression. This Phase 2b study is a,multi-center, ... patients with bipolar depression will receive,either RG2417 or ...
... SALT LAKE CITY, Nov. 6 "In a remarkable ... history of cosmetics, women around the,country have been applying ... of fine lines, wrinkles and crows, feet." Five years ... a revolution in the cosmetic,industry: a little-known American stretch-mark ...
... 6 Performance Health Technologies,Inc. (PHT), a leader ... guide and monitor exercise and rehabilitation, announced,today that ... the September 5 edition of "60 Second Science," ... "Virtual Rehabilitation: Wireless Motion Sensor to Help,Treat That ...
... NEW YORK, Nov. 6 According to the ... The African,American community is one of the groups ... diagnosed. With November being National Diabetes Month,Black Expressions(R) ... that raise,awareness about diabetes and offer information about ...
... Salud to Use Pan-Enterprise Search Platform to,Identify ... and SAN FRANCISCO, November 6 /PRNewswire-FirstCall/,-- Autonomy ... global leader in,infrastructure software for the enterprise ... Spain,s most innovative health service,provider, has selected ...
Cached Medicine News:Health News:Innovative Deep Vein Thrombosis Treatment Yields Priceless Payoff 2Health News:Innovative Deep Vein Thrombosis Treatment Yields Priceless Payoff 3Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 2Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 3Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 4Health News:Happy Birthday, StriVectin! The Skin Cream that Revolutionized the Anti-Aging Market 2Health News:Happy Birthday, StriVectin! The Skin Cream that Revolutionized the Anti-Aging Market 3Health News:Performance Health Technologies Garners Additional Media Coverage, Including Scientific American's News Blog 2Health News:Performance Health Technologies Garners Additional Media Coverage, Including Scientific American's News Blog 3Health News:National Diabetes Month Book Suggestions From Black Expressions(R) Book Club 2Health News:Leading Spanish Health Service Provider Selects Autonomy for Innovation in Healthcare 2Health News:Leading Spanish Health Service Provider Selects Autonomy for Innovation in Healthcare 3Health News:Leading Spanish Health Service Provider Selects Autonomy for Innovation in Healthcare 4
... management software - was designed by ... improvement tool helps diabetes care providers ... bridges medicine with technology by providing ... information technology product. This diabetes ...
... of diabetes in order to maintain tight control ... way to reduce or even prevent diabetes-related complications. ... a diabetes patients quality of life, however, is ... been the guiding factors in the development of ...
... the CGMS System Gold can assist you ... based on detailed glycemic profiles. Its also ... motivation and collaboration with patients.1, ,While ... all diabetes patients, it may be of ...
... The GlucoWatch G2 Biographer is intended for ... levels in adults (aged 18 and older) ... diabetes. Parents should supervise the use of ... G2 Biographer is intended to supplement, not ...
Medicine Products: